1697 results about "Urology" patented technology

The invention relates to the technical field of biology, in particular to a swelling hippocampal peptide as well as a preparation method and application thereof. Comprising a polypeptide with an amino acid sequence as shown in SEQ ID NO.1. The hippocampus antioxidative peptide is prepared by adopting an ultrahigh pressure pretreatment and enzymolysis technology, the adopted extraction process is simple in route, and the time and the production cost are effectively saved; an animal model is utilized to prove the antioxidation effect and the effect of improving male reproductive disorder and testis injury of the hippocampal swelling peptide; and on the basis, a novel peptide fragment with high activity, no toxicity and no sensitization is obtained.

Provided herein are compositions and methods for treating patients with Usher syndrome associated retinitis pigmentosa (UARP) comprising identifying that the subject has UARP and administering to the animal or human an effective amount of an N-acetylcysteine amide (NACA) sufficient to protect vision and inhibit degradation of Ellipsoid Zone (EZ) area and retinal sensitivity. In one example, the NACA formulation is doses at 50, 100, 200, 201, 210, 225, 250, 275, 300, 350, 400, 450, 500, 600, 700, 750, 800, 900, or 1,000 mg / day.

This invention belongs to the field of cosmetic technology, specifically relating to a composition for skin barrier repair and anti-inflammation after non-surgical cosmetic procedures and its application. The composition comprises Xinjiang comfrey peptide and Xinjiang comfrey naphthoquinone, with a mass ratio of 50-200:1. This composition synergistically inhibits the release of LPS-induced inflammatory factors, alleviating acute inflammatory reactions such as redness and burning after cosmetic procedures, achieving a dual effect of anti-inflammation and repair. The composition significantly reduces postoperative inflammatory redness and improves discomfort symptoms such as dryness and stinging. Through a multi-target mechanism, this invention solves the technical problems of existing repair products having single functions and slow onset of action, providing a highly efficient and comprehensive repair solution for skin after cosmetic procedures.

The present disclosure relates to flavor compositions and pet food products for preventing and / or treating chronic kidney disease (CKD) and / or urinary tract disease in an animal. In certain embodiments, the flavor compositions and pet food products have enhanced palatability.

The invention includes methods of preventing or treating acute lung injury using a MAP3K2 / MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

Device and methods for detection of kidney cancer using urine samples are disclosed herein. The device and methods enable isolation and quantification of kidney tumor cells in urine samples from a subject in need thereof.

Some embodiments are directed to a skin treatment system that contains a laser generating device. A hydrogel patch may include a region, at a first side of the hydrogel patch, to be in contact with a person's skin. The region may contain an adsorbing medium (e.g., carbon black or any other substance that would have a similar effect) that, when receiving a laser beam from the laser generating device, results in Extracorporeal Shock Wave Therapy (“ESWT”) being applied to the person's skin to treat a dermatologic condition such as an epidermal or dermal tissue structure irregularity, cellulite, a stretch mark, a scar, scar-tissue, a hypertrophic scar, an acne scar, etc.

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

Provided is a composition for visual field defect disorders, glaucoma, light-induced ocular tissue damage and related disorders, which can be used as a food or drug for long-term administration, prevention, symptom relief and improvement. A composition comprising a triglyceride represented by the formula (I):(wherein R1, R2, and R3 are each a saturated fatty acid residue, and at least one of them is a pentadecanoic acid residue) as an active ingredient.

Methods and compositions for treating acute kidney injury in a subject are provided. The methods include measuring or having measured a level of soluble urokinase plasminogen activator receptor (suPAR) in a biological sample from the subject, determining or having determined the level of suPAR in the sample compared to a control suPAR level, and administering a therapeutically effective amount of an agent that antagonizes soluble urokinase plasminogen activator receptor (suPAR) to the subject having an elevated level of suPAR relative to the control suPAR level.

The invention provides a urine detection method and device for a three-hour nine-diagnosis method, which comprises the following steps: firstly detecting the temperature of urine, then distinguishing whether the urine is in a hot period, a warm period or a cold period of three hours according to the measured temperature of the urine, then respectively measuring corresponding parameters in nine parameters according to the three hours, measuring the color, steam, foam and smell of the urine in the hot period, and measuring the color, steam, foam and smell of the urine in the cold period. Measuring precipitates and floating foam of the urine in a warm period, and measuring a steam dissipation state, an edge change state and a sticky state after stirring of the urine in a cool period. The device is suitable for the Tibetan medicine three-time-nine diagnosis method for urine, can quantitatively detect relevant parameter indexes of the urine, especially foam, and is beneficial to improving the effect of the Tibetan medicine three-time-nine diagnosis method.

The present application belongs to the technical field of ostomy base plate, and particularly relates to a leakage-proof ostomy base plate for postoperative colorectal cancer, which comprises a suction cup, the upper side wall of the suction cup is fixedly connected with a connecting cylinder, the outer wall of the connecting cylinder is fixedly sleeved with two limiting rings matched with an ostomy bag, the outer wall of the suction cup is fixedly sleeved with an adhesive layer, the inner wall of the connecting cylinder is fixedly connected with an elastic film, and a center hole is formed in the center position of the elastic film. Before the ostomy base plate is used, the size and shape of the center hole of the ostomy base plate can be freely adjusted according to the use condition, so that the leakage risk of excrement caused by the size deviation of the manually cut traditional fixed circular center hole is avoided, the compression damage of the ostomy mucosa caused by the too small cutting is eliminated, the sealing property of the base plate and the skin around the ostomy is improved, the complications such as fecal dermatitis are reduced, the nursing operation difficulty is reduced, and the wearing comfort and the life quality of the patient are improved.

Use of an effective amount of the bioactive peptide in the preparation of a medicament for the prevention and / or treatment of hypoxic-ischemic encephalopathy in newborns, wherein the amino acid sequence of the bioactive peptide contains KKNRNKLRRQHSY or a functionally equivalent variant thereof. Optionally, the bioactive peptide further comprises a signal peptide at its N-terminus or C-terminus.

The present invention relates to compositions, methods, uses and kits for the treatment of renal cystogenesis. In particular, the compositions, methods, uses and kits are particularly useful, but not limited to, the treatment or prevention of Polycystic Kidney Disease. In one aspect, the prevent invention provides a method of minimising or delaying renal cystogenesis in a subject in need thereof, the method comprising inhibiting AKT in the subject, or reducing the level of Aurora kinase in the subject, thereby minimising or delaying renal cystogenesis.

Disclosed herein are improved methods for treating muscular dystrophy, such as DMD, BMD, or FSHD. Various combination therapies and monotherapies are provided.

To provide a pump configured to be deployed in a patient's body.SOLUTION: A pump assembly for increasing urine output from a patient includes at least one ureteral catheter 614 including a distal portion having a retention portion 624 configured to be positioned in a kidney, renal pelvis, and / or ureter of the patient and a proximal portion defining a drainage lumen. The retention portion includes at least one drainage port 626 that permits fluid flow into the drainage lumen. The pump assembly further includes a pump 612 configured to provide negative pressure to at least one of the renal pelvis or the kidney through the drainage lumen of the at least one ureteral catheter. The pump includes at least one fluid port in fluid communication with the drainage lumen of the proximal portion of the ureteral catheter for receiving fluid from the patient's kidney, and at least a portion of the pump is configured to be positioned within the patient's body.SELECTED DRAWING: Figure 15A

The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a minoxidil solution for androgenetic alopecia, which takes a deep eutectic solvent as a core solvent system and contains 1.0-5.0% of minoxidil (active ingredient), 0.1-1.0% of preservative, 0.05-1% of stabilizer, a proper amount of sodium hydroxide (the pH value is adjusted to 4-9) and purified water. According to the minoxidil solution, the solubility of minoxidil is greatly improved through the deep eutectic solvent, the solubility of minoxidil reaches 779.85 mg / ml and is 389.9 times that of water, the deep eutectic solvent is used in the minoxidil solution, ethanol is not contained, the dosage of propylene glycol is as low as 3%, ethanol and high-dosage propylene glycol (20%-50%) in a traditional commercially available formula are prevented from being used, irritation to scalp is reduced, and the minoxidil solution is suitable for scalp care. The minoxidil solution is stable in content after 6 months under the condition of 40 DEG C / 60% RH, the in-vitro transdermal performance of the minoxidil solution is superior to that of a commercially available reference preparation of an ethanol and propylene glycol solvent system, and the minoxidil solution also has the advantages of high stability, remarkable hair growth ability and the like.

The invention discloses application of hydrogen-rich water in preparation of a drug for treating Duchenne type muscular dystrophy, and particularly relates to the technical field of medicines.The random control experiment is adopted, homologous c57 mice serve as a normal control group, mdx mice are randomly divided into a model group and a hydrogen-rich water group, and the exercise ability is evaluated through a four-limb holding power test and a rotating bar test; detecting mouse creatine kinase by an enzyme-linked immunosorbent assay; carrying out hematoxylin-eosin, NADH-tetrazole reductase and improved Goori three-color dyeing, and carrying out cytochrome C oxidase, succinate dehydrogenase and SDH-COX combined dyeing to observe the pathological change of the skeletal muscle tissue; the invention discloses that the muscle injury condition of a Duchenne type muscular dystrophy model mouse is improved by the hydrogen-rich water through a mitochondrial protection mechanism, and the hydrogen-rich water has a relatively high application prospect and a relatively high economic value.

Systems, methods and computer-readable media are provided for identifying patients having an elevated near-term risk of chronic kidney disease (CKD) progression, including predicting an individual's risk of progression to Stage 3 CKD within a future time interval, which may be up to 36 months. Based on the prediction, appropriate care providers may be notified so that the risk of CKD progression may be mitigated. In an embodiment, measurements of physiological variables are obtained, including serial measurements for uric acid levels from a longitudinal time series of serum or plasma samples spanning the previous two to five years. An annualized uric acid velocity of the patient is determined and used to generate a multivariable mathematical model for determining a likelihood of risk for developing Stage 3 CKD within 36 months.

This article provides methods for treating progressive familial intrahepatic cholestasis of blood (PFIC), including, for example, PFIC2 (bial salt export pump (BSEP) deficiency), using ileal bile acid transport (IBAT) inhibitors (such as ozexibart or a pharmaceutically acceptable salt thereof). These methods may include identifying or selecting subjects with a higher percentage of unconjugated serum bile acids relative to a reference level and administering an IBAT inhibitor to the identified or selected subject.

The invention relates to the technical field of molecular biology, in particular to a methylation marker for diagnosis of diabetic nephropathy. Specifically, the methylation marker comprises a P site of a CAT gene promoter region and / or an E site of a CAT gene exon 1 region. Based on a detection system combining methylation sensitive restriction enzyme with quantitative PCR, the kit has the advantages of simplicity and convenience in operation, good repeatability, accuracy in quantification and easiness in standardization, and is suitable for low-invasive samples such as peripheral blood. By effectively distinguishing pure type 2 diabetes patients from diabetic nephropathy combined patients, a reliable technical means is provided for risk stratification, early intervention and dynamic monitoring of diabetic people, and the method has good clinical application prospects and popularization value.

The present disclosure relates to methods of administering thyroid hormone receptor agonists. The present disclosure provides methods wherein the methods maintain the activity of a given thyroid receptor agonist in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related conditions, meanwhile, thyroid-related and thyroid axis-related side effects are reduced or eliminated.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a topical delay spray and its preparation method. The invention uses the dried epidermis of the Huaxi toad (with the toad venom removed), and extracts it efficiently through a combination of water and alcohol extraction. Male silkworm moth oil can nourish and strengthen the body, tonify the liver and kidneys, and combat fatigue; studies have shown that male silkworm moth oil can effectively treat kidney yang deficiency. This invention combines the synergistic effects of toad skin extract and male silkworm moth oil to prepare a delay spray that can significantly treat premature ejaculation and erectile dysfunction in men. This preparation has the advantages of direct action, sustained release, avoidance of drug contact, and simple operation. This invention further improves the rational utilization system of toad resources, provides a practical solution for the efficient development of toad medicinal resources, and significantly reduces production and clinical application costs.

1. Name of this design product: Patient pants with urine bag. 2. Purpose of this design: The patient's pants have a concealed opening in the side pocket, which facilitates the insertion and removal of the urine bag when the patient is carrying it, making it convenient to carry the urine bag. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key features: the front view. 5. This design is for a thin product, therefore the left view, right view, top view, and bottom view are omitted.

The invention discloses a polygala tenuifolia aqueous extract as well as a preparation method and application thereof, and the preparation method comprises the following steps: (1) removing impurities from a polygala tenuifolia medicinal material, and crushing to obtain polygala tenuifolia coarse powder for later use; (2) putting the polygala tenuifolia coarse powder obtained in the step (1) and pure water into an extraction device according to a solid-liquid ratio of 1: (10-15) (g / mL), and extracting for 2-3 times while keeping a slight boiling state; (3) after each time of extraction in the step (2) is finished, filtering, and collecting filtrate of each time to obtain a polygala tenuifolia water extract; and (4) concentrating and drying the polygala tenuifolia water extract in the step (3) to obtain polygala tenuifolia water extract dry powder. The polygala tenuifolia aqueous extract is used as an effective component to prepare the external medicament for treating the red and swollen skin, so that the limitation of dosage forms such as original water decoction or medicine residue external application is broken through, the transdermal absorption and the curative effect are remarkably improved, the efficient local treatment of the skin abscess is realized, and the problems of systemic side effects and drug resistance of antibiotics caused by oral medicines are avoided; the applicable crowd is expanded.